Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
- PMID: 16966688
- DOI: 10.1200/JCO.2006.06.0483
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
Abstract
Purpose: Chemotherapy resistance in melanoma has been linked to antiapoptotic effects mediated by Bcl-2 protein. We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma.
Patients and methods: We randomly assigned chemotherapy-naïve patients with advanced melanoma to treatment with dacarbazine (1,000 mg/m2) alone or preceded by a 5-day continuous intravenous infusion of oblimersen sodium (7 mg/kg/d) every 3 weeks for up to eight cycles. Patients were stratified by Eastern Cooperative Oncology Group performance status, liver metastases, disease site, and serum lactate dehydrogenase (LDH). The primary efficacy end point was overall survival.
Results: Among 771 patients randomly assigned, the addition of oblimersen to dacarbazine yielded a trend toward improved survival at 24-month minimum follow-up (median, 9.0 v 7.8 months; P = .077) and significant increases in progression-free survival (median, 2.6 v 1.6 months; P < .001), overall response (13.5% v 7.5%; P = .007), complete response (2.8% v 0.8%), and durable response (7.3% v 3.6%; P = .03). A significant interaction between baseline serum LDH and treatment was observed; oblimersen significantly increased survival in patients whose baseline serum LDH was not elevated (median overall survival, 11.4 v 9.7 months; P = .02). Neutropenia and thrombocytopenia were increased in the oblimersen-dacarbazine group; however, there was no increase in serious infections or bleeding events.
Conclusion: The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.
Comment in
-
Reaching first base in the treatment of metastatic melanoma.J Clin Oncol. 2006 Oct 10;24(29):4673-4. doi: 10.1200/JCO.2006.07.3593. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966683 No abstract available.
-
Molecular classification of patients with malignant melanoma for new therapeutic strategies.J Clin Oncol. 2007 Jun 1;25(16):e20-1. doi: 10.1200/JCO.2007.11.0965. J Clin Oncol. 2007. PMID: 17538155 No abstract available.
Similar articles
-
Oblimersen in the treatment of metastatic melanoma.Future Oncol. 2007 Jun;3(3):263-71. doi: 10.2217/14796694.3.3.263. Future Oncol. 2007. PMID: 17547520 Review.
-
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.Melanoma Res. 2014 Jun;24(3):237-43. doi: 10.1097/CMR.0000000000000056. Melanoma Res. 2014. PMID: 24667300 Clinical Trial.
-
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).Eur J Cancer. 2009 Jul;45(10):1807-14. doi: 10.1016/j.ejca.2009.04.016. Epub 2009 May 4. Eur J Cancer. 2009. PMID: 19419855 Clinical Trial.
-
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.J Clin Oncol. 2007 Mar 20;25(9):1114-20. doi: 10.1200/JCO.2006.07.1191. Epub 2007 Feb 12. J Clin Oncol. 2007. PMID: 17296974 Clinical Trial.
-
Apoptosis, Bcl-2 antisense, and cancer therapy.Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):5-10. Oncology (Williston Park). 2004. PMID: 15651171 Review.
Cited by
-
Non-coding RNAs as skin disease biomarkers, molecular signatures, and therapeutic targets.Hum Genet. 2023 Aug 14. doi: 10.1007/s00439-023-02588-4. Online ahead of print. Hum Genet. 2023. PMID: 37580609 Review.
-
Pharmacological Targeting of Bcl-2 Induces Caspase 3-Mediated Cleavage of HDAC6 and Regulates the Autophagy Process in Colorectal Cancer.Int J Mol Sci. 2023 Apr 3;24(7):6662. doi: 10.3390/ijms24076662. Int J Mol Sci. 2023. PMID: 37047634 Free PMC article.
-
Immunotherapy in Melanoma: Recent Advances and Future Directions.Cancers (Basel). 2023 Feb 9;15(4):1106. doi: 10.3390/cancers15041106. Cancers (Basel). 2023. PMID: 36831449 Free PMC article. Review.
-
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials.Clin Transl Oncol. 2023 Jun;25(6):1554-1578. doi: 10.1007/s12094-022-03070-9. Epub 2023 Jan 13. Clin Transl Oncol. 2023. PMID: 36639602 Free PMC article. Review.
-
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics.Cancer Discov. 2022 May 2;12(5):1217-1232. doi: 10.1158/2159-8290.CD-21-1334. Cancer Discov. 2022. PMID: 35491624 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical